Our recent PD0325901 mouse study found that the most abundant isoform Txl-2b in colon cancer stimulated cancer cell metastasis. However, the role of Txl-2b in tumor growth was still unknown. Methods: In this study, the function of Txl-2b on cell proliferation and apoptosis were investigated, accompanied with the downstream signaling. Results: Inhibition of Txl-2b led to the suppression of proliferation, cell

cycle arrest at the G1/S phase of the cell cycle, and induction of 5-fluorouracil-induced apoptosis in SW620 cells, whereas overexpression of Txl-2b in LoVo cells led to the opposite effect. In vivo study validated that Txl-2b may promote colon cancer tumorigenesis in nude mice. Further studies revealed that the nuclear factor-κB (NF-κB) signal was activated by Txl-2b through a redox-dependent manner. SN50, a specific inhibitor of NF-κB, partly abrogated the in vitro phenotypes of cell proliferation and resistance of apoptosis induced by Txl-2b through reduced expression of Bcl-2, as well as increased expression of Bax and caspase-3 and -7 activation. Conclusion: Overall, the present study indicates that Txl-2b

stimulates cancer cell proliferation, accelerates cell cycle and contributes to resistance of apoptosis in colon cancer and provides a potential therapeutic target for the treatment of colon cancer. Key Word(s): 1. colon cancer; 2. proliferation; 3. apoptosis; 4. thioredoxin-like 2; Presenting Author: LIANG YU FEI Additional Authors: ZHENG GUO QI, WEI SI CHEN, SONG HUI, YANG YU XIN, YIN WEN JIE, ZHANG XIU GANG Corresponding Author: ZHENG GUO QI Affiliations: hebei medical univercity Objective: To explore the clinical http://www.selleckchem.com/products/Y-27632.html features of localized peritoneal mesothelioma by the analysis of the clinical data

of them and asbestos exposure relationship in our hospital. Methods: We collected clinical information of patients with pathologically confirmed localized peritoneal mesothelioma GPX6 in our hospital for the past six years, to analyze the incidence, asbestos exposure history, clinical manifestations, imaging studies, histological type and tumor markers of peritoneal malignant mesotheliom patients. Results: 189 cases of patients with PMM were treated in our hospital, including 22 cases of localized peritoneal mesothelioma which accounting for 11.64%. In 22 cases, 63.63% had history of asbestos exposure, and women accounted for 68.18%. The onset of symptoms to treatment time was from 2 days to 1 year, with an average of 83 days. Clinical symptoms were vary including localized abdominal pain, abdominal distension and abdominal mass. Local peritoneal mass or local inflammation was more common by abdominal CT, In addition, some patients with ascites. Epithelial type was the main athological type. Ultrasound-guided peritoneal biopsy was confirmed as the main diagnostic method followed by Laparotomy. Platelet and CA125 were increased.